RecruitingNot ApplicableNCT06692140

Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated with Percutaneous Coronary Intervention

Randomized Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated with Percutaneous Coronary Intervention in an All Comer Population (The SORT OUT XII Trial)

Sponsor

Odense University Hospital

Enrollment

3,150 participants

Start Date

Nov 16, 2024

Study Type

INTERVENTIONAL

Conditions

Coronary Artery Disease Percutaneous Coronary Intervention (PCI)Ischemia, Myocardial

Summary

The objective of this randomized study is to compare the safety and efficacy of the ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent to the everolimus-eluting family stents (durable polymer everolimus-eluting Xience or Promus stents) in a population-based setting with coronary artery stenosis treated with percutaneous coronary intervention

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called PCI with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s)) and a medical device called Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s) for people with coronary artery disease, ischemia, myocardial, and other related conditions. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEUltra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)

Percutaneous coronary intervention with Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)

DEVICEPCI with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))

Percutaneous coronary intervention with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))

Locations(3)

Aalborg University Hospital

Aalborg, Denmark

Aarhus University Hospital

Aarhus, Denmark

Odense University Hospital

Odense, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06692140

Related Trials

Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

NCT0677963023 locations

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions

NCT072582902 locations

Revascularization of Calcified Coronary Arteries

NCT077241841 location

Virtue® SAB in the Treatment of Coronary ISR Trial

NCT0704519415 locations

CPB and Aortic Cross-Clamp Durations and ICU Length of Stay After CABG Retrospective Observational Cohort Study

NCT077119511 location